Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Somatropin (ATC-Code nach WHO: H01AC01)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Somatropin (ATC-Code nach WHO: H01AC01)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum purchase quantities; actual demand is unknown and depends on external factors (prescription behavior, pharma...
Buyer may terminate the Open-House process early if exclusive agreements are concluded, which typically happen 8-12 mon...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jul 2026
- Conclusion of non-exclusive discount agreements for Somatropin (ATC H01AC01) under §130a Abs. 8 SGB V.
- Open-House model: any qualifying pharmaceutical enterprise can participate.
Show full summary
Non-exclusive pharmaceutical discount agreement for Somatropin (H01AC01) via an Open-House model. Open to all pharmaceutical enterprises meeting conditions. No guaranteed purchase volumes, no exclusivity. Contract ends by 31.07.2026. First submission deadline: 05.07.2024, with rolling deadlines until 31.07.2026. Only one lot identified. Estimated value not provided.
Risks
No minimum purchase quantities; actual demand is unknown and depends on external factors (prescription behavior, pharma...
Buyer may terminate the Open-House process early if exclusive agreements are concluded, which typically happen 8-12 mon...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Participant must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG for the offered medicinal products.
- Participant must have its seat in Germany, EU, or EEA (§9 Abs. 2 Satz 1 AMG).
Administrative
- Submission via DTVP portal after requesting access to the project room.
Requirements may be incomplete.
Buyer
Name
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Somatropin (ATC-Code nach WHO: H01AC01)
Non-exclusive discount agreement for Somatropin. Open-House model, no negotiations, no exclusivity, unknown quantities.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 31 May 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 323563-2024
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum purchase quantities; actual demand is unknown and depends on external factors (prescription behavior, pharma...
Buyer may terminate the Open-House process early if exclusive agreements are concluded, which typically happen 8-12 mon...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications